Biogen Idec 3Q 3Q Revenues: $1.2 billion (+5%) 3Q Earnings: $254 million (-8%) YTD Revenues: $3.5 billion (+8%) YTD Earnings: $765.0 million (+15%) Comments: Avonex revenues increased 11% to $644 million in the quarter and Tysabri revenues were up 7% to $221 million. Rituxan revenues were down 9% to $258 million. Royalty revenues were $36 million in the quarter (+3%). Biogen sells Tysabri through a partnership with Elan Corp. and markets Rituxan with Roche’s Genentech divisi...